. 2021 Apr 29;9:e11366. doi: 10.7717/peerj.11366

Table 1. Correlation of recurrence and recurrence-free-survival (RFS) with patient demographics and clinicopathological characteristics.

Parameter	n	Recurrence	P	RFS (P)*	D-recurrence	P	D-RFS (P)*
Age
<53	19	7	0.1279	0.062	5	0.408	0.193
≧53	17	2	0.1279	0.062	2	0.408	0.193
TNM stage
II	29	5	0.0497	0.033	4	0.1159	0.093
III	7	4	0.0497	0.033	3	0.1159	0.093
T stage
T1	5	1	0.2193	0.11	1	0.8124	0.666
T2	28	6			5
T3	3	2			1
N stage
N0	15	2	0.0643	0.083	2	0.0309	0.053
N1	14	4			2
N2	5	1			1
N3	2	2			2
Differentiation
I	13	5	0.216	0.195	4	0.364	0.327
II	11	3			2
III	12	1			1
ER
Yes	27	7	1	0.855	5	1	0.818
No	9	2	1	0.855	2	1	0.818
PR
Yes	21	5	1	0.919	5	0.6738	0.452
No	15	4	1	0.919	2	0.6738	0.452
HER2
Yes	10	4	0.2262	0.134	3	0.3696	0.237
No	26	5	0.2262	0.134	4	0.3696	0.237
Menopause
Yes	21	5	1	0.754	3	0.4178	0.316
No	15	4	1	0.754	4	0.4178	0.316
Ad chemo TX
Yes	29	8	0.6518	0.374	7	0.3029	0.13
No	7	1	0.6518	0.374	0	0.3029	0.13
Ad rad TX
Yes	23	8	0.1136	0.109	7	0.0343	0.047
No	13	1	0.1136	0.109	0	0.0343	0.047
Ad hor TX
Yes	28	7	1	0.945	5	0.639	0.637
No	8	2	1	0.945	2	0.639	0.637
Ad tar TX
Yes	10	4	0.2262	0.134	2	1	0.134
No	26	5	0.2262	0.134	5	1	0.134
CTCs
≧4	9	5	0.0262	0.013	4	0.0497	0.029
<4	27	4	0.0262	0.013	3	0.0497	0.029

Notes:

Follow-up (days): min = 128; max = 723; mean = 518; median = 536.

Abbreviation: n = number; RFS = recurrence-free survival; D = distant; D-RFS = distant recurrence-free survival; TNM = tumor-node-metastasis; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor-2; Ad chemo TX = adjuvant chemotherapy; Ad rad TX = adjuvant radiation therapy; Ad hor TX = adjuvant hormonal therapy; Ad tar TX = adjuvant targeted therapy; CTCs = circulating tumor cells.